From Tumor Biology to Therapeutic Design: Expert Insights…
Two Vector scientists were recently interviewed about glycosylation in cancer research and advances in bioconjugation for next-generation therapeutics.
From linker design and synthesis, bioconjugated design and manufacturing, biomolecule labeling and functionalization, and detection system and solutions, our team is here to help you move forward, with impact.
Explore our custom approach to science:

Vector Laboratories will be attending Cancer Glyco-X 2026 to discuss how the right tools reveal glyco-insights in cancer research. Product Manager Shuhui Chen and Sr. Field Application Scientist Sabrina Mateos will be representing Vector Laboratories at the Van Andel Institute from May 5-6 and are looking forward to sharing new methods for spatially analyzing protein … Continued
Immune checkpoint therapy describes a class of antibody therapeutics for the treatment of cancer that target proteins that modulate immune responses. More than a dozen approved therapeutics target immune checkpoint proteins like PD-1, PD-L1, and CTLA-4 [1]. These therapies show success in a variety of cancer types and have revolutionized cancer immunotherapy by ramping up … Continued